Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Observational

Motor Competence and Physical Activity in Children Aged 4-6: Associations With Parental Perceptions

NCT07366957 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-01-10
Last updated
2026-01-29

Condition(s) studied

Motor DevelopmentPhysical Activity

Study summary

This study aims to determine motor competence and physical activity levels in children aged 4-6 years and to explore their relationship with parental perceptions. The study will use a qualitative research approach supported by quantitative assessments. Children's motor competence will be evaluated using the Peabody Developmental Motor Scales-Second Edition (PDMS-II), while parents will participate in semi-structured interviews to explore their perceptions, attitudes, and experiences related to their children's motor development and physical activity. Data will be collected in educational settings without any intervention. The findings are expected to contribute to a better understanding of family-related factors influencing motor development in early childhood.

Eligibility

Sex
ALL
Min age
4 Years
Max age
6 Years
Healthy volunteers
Accepted
Inclusion Criteria: Children * Children aged 4-6 years based on chronological age, * Children without any physician-diagnosed physical, intellectual, or neurological disorders, * Children born at term (≥37 weeks of gestation), * Children with no history of serious perinatal or postnatal complications (e.g., prolonged neonatal intensive care unit stay, intracranial hemorrhage, requirement for advanced respiratory support), * Children able to independently complete the motor assessment tests used in the study. Parents * Parents who voluntarily agree to participate in the study and provide written informed consent, * Parents with sufficient proficiency in reading, understanding, and expressing -themselves in Turkish, * Parents who are the primary caregivers of the child included in the study. Exclusion Criteria: Children * Children younger than 4 years or older than 6 years, * Children with a history of preterm birth (\<37 weeks of gestation), * Children with any physician-diagnosed neurological, physical, developmental, or chronic conditions (e.g., cerebral palsy, pervasive developmental disorders, genetic syndromes, musculoskeletal disorders), * Children with congenital or acquired orthopedic conditions that prevent completion of the motor tests used in the study, * Children with attention, behavioral, or communication difficulties that would prevent completion of the test procedures. Parents * Individuals who have difficulty communicating in Turkish or are unable to participate in the interview process, * Parents who do not complete the interview process, do not consent to audio recording, or voluntarily withdraw from the study were defined as exclusion criteria.

Primary outcome measure(s)

  • Motor Development Scores (PDMS-II) — 12/2025-04/2026
    Children's gross and fine motor skills will be assessed using the Peabody Developmental Motor Scales - Second Edition (PDMS-II). The PDMS-II consists of gross motor and fine motor subtests and yields standard scores and composite scores. Raw scores are converted to standard scores, with a possible score range of 1 to 20 for subtests, and composite motor quotients ranging from 35 to 165. Higher scores indicate better motor performance and more advanced motor development. This measure provides objective and standardized data on motor development in children aged 4-6 years.

Trial sites (1)

FacilityCityRegionStatus
Mudanya University, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation/Afyonkarahisar University of Health Sciences - Atatürk Vocational School of Health Services - Physiotherapy Program Bursa Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07366957 on ClinicalTrials.gov ↗ ← All trials in Turkey